Intercept Pharma (ICPT) FLINT Trial Data Shows OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH
Tweet Send to a Friend
Intercept Pharma (NASDAQ: ICPT) announced overnight that the availability of additional post-hoc analyses from the Phase 2b FLINT trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
